Increased expression of thioredoxin/adult T-cell leukemia-derived factor in cisplatin-resistant human cancer cell lines

Clinical Cancer Research

Volumn 2, Issue 2, 1996, Pages 427-432

  Yamada, Manabu ^a,b   Tomida, Akihiro ^a   Yoshikawa, Hiroyuki ^b   Taketani, Yuji ^b   Tsuruo, Takashi ^a,c  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GLUTATHIONE; THIOREDOXIN;

ARTICLE; CANCER; CONTROLLED STUDY; DRUG RESISTANCE; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; T CELL LEUKEMIA; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CISPLATIN; CYTOKINES; DRUG RESISTANCE, NEOPLASM; GLUTATHIONE; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; THIOREDOXIN; THIOREDOXIN REDUCTASE (NADPH); TUMOR CELLS, CULTURED;

EID: 0029938958     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Clark, J. R., and Dreyfuss, A. I. The role of cisplatin in treatment regimens for squamous cell carcinoma of the head and neck. Semin. Oncol, 18: 34-48, 1991.
2. Williams, S. D., and Einhorn, L. H. cis-platinum in the treatment of testicular and other cancers Adv. Intern. Med., 27: 531-545, 1982.
3. Raghavan, D., Pearson, B., Watt, W. H., Mameghan, H., Langdon, P., Eisinger, D., and Wines, R. Cytotoxic chemotherapy for advanced bladder cancer: cisplatin-containing regimens. Semin. Oncol., 18, 56-63, 1991.
4. Ozols, R F., Thigpen, J. T., Dauplat, J., Colombo, N., Piccart, M. J., Bertelsen, K., Levin, L., and Lund, B. Advanced ovarian cancer. Dose intensity. Ann. Oncol., 4: 49-56, 1993.
5. Parker, R. J., Eastman, A., Bosstick-Bruton, F., and Reed, E Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J. Clin. Invest., 87: 772-777, 1991.
6. Oldenburg, J., Begg, A. C., Vugt, M. J. H. v., Ruevekamp, M., Schornagel, J. H., Pinedo, H. M., and Los, G Characterization of resistance mechanisms to cis-diaminedichloroplatinum(II) in three sublines of the CC531 adenocarcinoma cell line in vitro. Cancer Res., 54: 487-493, 1994.
7. Godwin, A. K., Meister, A., O'Dwyer, P. J., Huang, C. S., Hamilton, T. C., and Anderson, M. E High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl. Acad. Sci. USA, 89, 3070-3074, 1992.
8. Kelley, S. L., Basu, A., Teicher, B. A., Hacker, M. P., Hamer, D. H., and Lazo, J. S. Overexpression of metallothionein confers resistance to anticancer drugs. Science (Washington DC), 241: 1813-1815, 1988.
9. Lai, G-M., Ozols, R F., Smyth, J. F., Young, R. C., and Hamilton, T. C. Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. Biochem. Pharmacol., 37: 4597-4600, 1988.
10. Ishikawa, T., and Ali-Osman, F. Glutathione-associated cis-diaminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. J. Biol. Chem., 268: 20116-20125, 1993.
11. Lai, G-M., Ozols, R. F., Young, R. C., and Hamilton, T. C. Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. J. Natl. Cancer Inst., 81: 535-539, 1989.
12. Holmgren, A. Thioredoxin. Annu. Rev. Biochem., 54: 237-271, 1985.
13. Fujii, S., Nanbu, Y., Nonogaki, H., Konishi, I., Mori, T., Masutani, H., and Yodoi, J. Coexpression of adult T-cell leukemia-derived factor, a human thioredoxin homologue, and human papillomavirus DNA in neoplastic cervical squamous epithelium. Cancer (Phila.), 68: 1583-1591, 1991.
14. Nakamura, H., Masutani, H., Tagaya, Y., Yamauchi, A., Inamoto, T., Nanbu, Y., Fujii, S., Ozawa, K., and Yodoi, J. Expression and growth-promoting effect of adult T-cell leukemia-derived factor. A human thioredoxin homologue in hepatocellular carcinoma. Cancer (Phila.), 69: 2091-2097, 1992.
15. Gasdaska, P. Y., Oblong, J. E., Cotgreave, I. A., and Powis, G. The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): thioredoxin mRNA is elevated in some human tumors. Biochim. Biophys. Acta, 1218: 292-296, 1994.
16. Nakamura, H., Matsuda, M., Furuke, K., Kitaoka, Y., Iwata, S., Toda, K., Inamoto, T., Yamaoka, Y., Ozaua, K., and Yodoi, J. Adult T cell leukemia-derived factor/human thioredoxin protects endothelial F-2 cell injury caused by activated neutrophils or hydrogen peroxide. Immunol. Lett., 42: 75-80, 1994.
17. Hori, K., Katayama, M., Sato, N., Ishii, K., Waga, S., and Yodoi, J. Neuroprotection by glial cells through adult T cell leukemia-derived factor/human thioredoxin (ADF/TRX). Brain Res., 652: 304-310, 1994.
18. Tomimoto, H., Akiguchi, I., Wakita, H., Kimura, J., Hori, K., and Yodoi, J. Astroglial expression of ATL-derived factor, a human thioredoxin homologue, in the gerbil brain after transient global ischemia. Brain Res., 625: 1-8, 1993.
19. Ohira, A., Honda, O., Gauntt, C. D., Yamamoto, M., Hori, K., Masutani, H., Yodoi, J., and Honda, Y. Oxidative stress induces adult T cell leukemia derived factor/thioredoxin in the rat retina. Lab. Invest., 70: 279-285, 1994.
20. Tagaya, Y., Maeda, Y., Mitsui, A., Kondo, N., Matsui, H., Hamuro, J., Brown, N., Arai, K., Yokota, T., Wakasugi, H., and Yodoi, J. ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologous to thioredoxin: possible involvement of dithiol-reduction in the IL-2 receptor induction. EMBO J., 8: 757-764, 1989.
21. Mitsui, A., Hirakawa, T., and Yodoi, J. Reactive oxygen-reducing and protein-refolding activities of adult T cell leukemia-derived factor/ human thioredoxin. Biochem. Biophys. Res. Commun., 186: 1220-1226, 1992.
22. Takatori, T., Koizumi, T., Tokui, T., Mitsuhashi, Y., Shirai, A., and Tsuruo, T. Intracellular activation and cytotoxic action of RS-1541 against cultured human tumor cells. Cancer Chemother. Pharmacol., 35: 283-290, 1995.
23. Alley, M. C., Scudieroo, D. A., Monks, A., Hursey, M L., Czerwinski, M. J., Fine, D. L., Abbott, B. J., Mayo, J. G., Shoemaker, R. H., and Boyd, M. R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res., 48: 589-601, 1988.
24. Lee, J-H., Naito, M., and Tsuruo, T. Nonenzymatic reductive activation of 7-N-{{2-{[2-(γ-L-glutamino)ethyl]dithio}ethyl}}mitomycin C by thiol molecules: a novel mitomycin C derivative effective on mitomycin C-resistant tumor cells. Cancer Res., 54: 2398-2403, 1994.
25. Tsuruo, T., Iida, H., Tsukagoshi, S., and Sakurai, Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res., 41: 1967-1972, 1981.
26. Kitaoka, Y., Sorachi, K., Nakamura, H., Masutani, H., Mitsui, A., Kobayashi, F., Mori, T., and Yodoi, J. Detection of adult T-cell leukemia-derived factor/human thioredoxin in human serum. Immunol. Lett., 41: 155-161, 1994.
27. Luthman, M., and Holmgren, A. Rat liver thioredoxin and thioredoxin reductase: purification and characterization. Biochemistry, 21: 6628-6633, 1982.
28. Huston, K., Silberstein, D., and Spriggs, D. Eosinophil cytotoxicity enhancing factor (ECEF) overexpression in human cancer cells with acquired cisplatin resistance. Proc. Am. Assoc. Cancer Res., 35: 438. 1994.
29. Mistry, P., Kelland, L R., Abel, G., Sidhar, S., and Harrap, K. R. The relationship between glutathione, glutathione-5-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br. J. Cancer, 64: 215-220, 1991.
30. Sugihara, K., and Gemba, M. Modification of cisplatin toxicity by antioxidants. Jpn. J. Pharmacol., 40: 353-355, 1986.
31. Masuda, H., Tanaka, T., and Takahama, U. Cisplatin generates superoxide anion by interaction with DNA in a cell-free system. Biochem. Biophys. Res. Commun., 203: 1175-1180, 1994.
32. Spitz, D. R., Phillips, J. W., Adams, D. T., Sherman, C. M., Deen, D. F., and Li, G. C. Cellular resistance to oxidative stress is accompanied by resistance to cisplatin: the significance of increased catalase activity and total glutathione in hydrogen peroxide-resistant fibroblasts. J. Cell Physiol., 156: 72-79, 1993.
33. Andrews, P. A., Murphy, M. P., and Howell, S. B. Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res., 45: 6250-6253, 1985.
34. Hamilton, T. C., Winker, M. A., Louie, K. G., Batist, G., Behrens, B. C., Tsuruo, T., Grotzinger, K. R., Mckoy, W. M., Young, R. C., and Ozols, R. F. Augmentation of Adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem. Pharmacol., 34: 2583-2586, 1985.
35. Meister, A. and Anderson, M. E. Glutathione, Annu. Rev. Biochem., 52: 711-760, 1983.
36. Fernando, M. R., Nanri, H., Yoshitake, S., Nagata, K. K., and Minakami, S. Thioredoxin regenerates proteins inactivated by oxidative stress in endothelial cells. Eur. J. Biochem., 209: 917-922, 1992.
37. Gilbert, H. F. Catalysis of thiol/disulfide exchange: single-turnover reduction of protein disulfide-isomerase by glutathione and catalysis of peptide disulfide reduction. Biochemistry, 28: 7298-7305, 1989.
38. Holmgren, A. Thioredoxin and glutaredoxin systems. J. Biol. Chem., 264: 13963-13966, 1989.
39. Mitomo, K., Nakayama, K., Fujimoto, K., Sun, X., Seki, S., and Yamamoto, K. Two different cellular redox systems regulate the DNA-binding activity of the p50 subunit of NF-kappa B in vitro. Gene, 145: 197-203, 1994.
40. Mayer, M., and Noble, M. N-acetyl-L-cysteine is a pluripotent protector against cell death and enhancer of trophic factor-mediated cell survival in vitro. Proc. Natl. Acad. Sci. USA, 91: 7496-7500, 1994.
41. Matsuda, M., Masutani, H., Nakamura, H., Miyajima, S., Yamauchi, A., Yonehara, S., Uchida, A., Irimajiri, K., Horiuchi, A., and Yodoi, J. Protective activity of adult T cell leukemia-derived factor (ADF) against tumor necrosis factor-dependent cytotoxicity on U937 cells. J. Immunol., 147: 3837-3841, 1991.
42. Kataoka, S., Naito, M., Tomida, A., and Tsuruo, T. Resistance to antitumor agent-induced apoptosis in a mutant of human myeloid leukemia U937 cells. Exp. Cell Res.,. 215: 199-205, 1994.
43. Barry, M. A. Behnke, C. A., and Eastman, A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia, Biochem. Pharmacol., 40: 2353-2362, 1990.
44. 2 phase and cell death induced by cisplatin. J. Natl. Cancer Inst., 82: 749-755, 1990.